This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human CRTAM Protein, His Tag
catalog :
CRM-H52H3
quantity :
1 mg, 100 ug
price :
1980 USD, 300 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
CRM-H52H3
product name :
Human CRTAM Protein, His Tag
quantity :
1 mg, 100 ug
price :
1980 USD, 300 USD
quantity & price :
$300/100ug,$1980/1mg
target :
CRTAM
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human CRTAM, His Tag (CRM-H52H3) is expressed from human 293 cells (HEK293). It contains AA Ser 18 - Gly 287 (Accession # O95727-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human CRTAM, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Class I-restricted T cell-associated molecule (CRTAM), a member of nectin family and the immunoglobulin superfamily, is also known as cytotoxic and regulatory T-cell molecule, which is expressed by activated CD8+ and NK T cells. CRTAM is found in spleen, thymus, small intestine, peripheral blood, and surprisingly, in brain where it is highly expressed by Purkinje cells of the cerebellum. The high affinity of CRTAM/IGSF4 adhesion allows CRTAM to disrupt IGSF4 homotypic interactions (3 - 5). IGSF4 and T cell receptor co-engagement of CRTAM-expressing CD8+ cells induces increased IFN-gamma or IL-22 production (3, 4). Furthermore, a role in cancer surveillance through NK cell-mediated rejection of IGSF4-expressing tumors has been proposed.
References :
(1) Arase N., et al., 2005, Int. Immunol. 17:1227.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments